Gillian Belbin, Senior Data Scientist - Jun 10, 2024

Enhancing genome-wide association analyses with whole genome data in the UK Biobank

The recent release of Whole Genome Sequencing (WGS) data for 490,640 participants in the UK Biobank (UKBB) has presented researchers with opportunities for comprehensive assessment of genomic risk factors underlying disease at an unprecedented resolution and scale. With the release of this data, we wanted to explore two traits of interest, Body Mass Index (BMI) and Type II Diabetes (T2D), to understand how increased resolution on genome-wide associations for these traits.

Read More >

Gencove Team - May 06, 2024

Genome-wide and phenome-wide associations: Advancing our understanding of the genetic contributions to health

Investigating the genetic basis of complex human traits is a pivotal endeavor in modern biomedical research. In a recent study, researchers at the Weizmann Institute of Science delved into a deep repository of clinical and genetic data to unravel the genetic associations across a range of disease phenotypes.

Read More >

Jeremy Li - Mar 23, 2023

An evaluation of imputation accuracy in a recently released open-access genomic dataset using low-pass sequencing

In this blog post, we describe some imputation performance benchmarks for a recently released haplotype reference panel from the Martin Lab comprising haplotypes from high-depth sequence data from the 1000 Genomes project and the Human Genome Diversity Project and compare them against corresponding benchmarks for the New York Genome Center's resequencing effort of the 1000 Genomes project.

Read More >

Josh Setton, Head of Sales - Jun 09, 2022

Three Ways Gencove’s Low-Pass Whole Genome Sequencing is Modernizing the Drug Discovery Process

Pharmaceutical companies use Whole Exome Sequencing (WES) in their drug discovery and development process. However, R&D teams still need a comprehensive view of genomic variation outside the exome. Historically, the only way to augment WES was with arrays, but now pharma companies have an alternative - low-pass whole genome sequencing.

Read More >